SIGA Technologies, Inc.

SIGA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $23.3M $59.2M $68.1M $33.9M $69.5M $56.3M $-7.2M $421.8M
Depreciation & Amortization $562.6K $538.4K $538.3K $517.6K $522.4K $529.8K $527.0K $69.6K
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $3.7M $3.6M $2.1M $1.8M $1.3M $1.4M $2.1M $2.3M
Net Cash from Operating Activities $43.5M $48.8M $94.8M $41.6M $11.5M $71.5M $-18.2M $68.9M
Investing Activities
Capital Expenditures — — — — — — $29.1K $102.3K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-355.0K $-42.5K $-21.7K $0 $-50.6K $-15.5K $-29.1K $78.2M
Financing Activities
Dividends Paid $43.1M $42.7M $32.1M $32.9M $0 $0 — —
Stock Repurchases $0 $0 $11.1M $13.0M $26.0M $28.5M $0 $0
Net Cash from Financing Activities $-43.6M $-43.5M $-43.4M $-46.0M $-26.2M $-114.6M $-1.2M $-3.8M
Net Change in Cash — — — — — — — $143.3M
Free Cash Flow — — — — — — $-18.2M $68.8M
← Newer Page 1 of 3 Older →